This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Zosano Pharma 将来の成長

Future 基準チェック /06

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Nov 02

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Jun 29

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

May 26

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Apr 30

Zosano shares rise on migraine treatment NDA resubmission update

Apr 26

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Mar 15

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

Feb 01

Zosano Pharma requests FDA meeting for its Qtrypta application

Jan 04

Zosano Pharma EPS misses by $0.01

Nov 13

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Zosano Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OTCPK:ZSAN.Q - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2022	1	-55	-31	-29	N/A
12/31/2021	1	-30	-33	-28	N/A
9/30/2021	1	-31	-34	-28	N/A
6/30/2021	1	-31	-39	-31	N/A
3/31/2021	0	-33	-41	-31	N/A
12/31/2020	0	-33	-40	-32	N/A
9/30/2020	N/A	-34	-41	-33	N/A
6/30/2020	N/A	-35	-43	-33	N/A
3/31/2020	N/A	-37	-45	-36	N/A
12/31/2019	N/A	-38	-47	-35	N/A
9/30/2019	N/A	-39	-46	-34	N/A
6/30/2019	N/A	-37	-43	-33	N/A
3/31/2019	N/A	-37	-40	-30	N/A
12/31/2018	N/A	-35	-35	-29	N/A
9/30/2018	N/A	-33	-33	-28	N/A
6/30/2018	N/A	-32	-30	-27	N/A
3/31/2018	N/A	-30	-28	-26	N/A
12/31/2017	N/A	-29	-28	-27	N/A
9/30/2017	N/A	-29	-29	-28	N/A
6/30/2017	N/A	-29	-27	-26	N/A
3/31/2017	N/A	-29	-24	-24	N/A
12/31/2016	N/A	-30	-26	-26	N/A
9/30/2016	N/A	-30	-26	-25	N/A
6/30/2016	N/A	-31	-28	-27	N/A
3/31/2016	0	-32	-28	-27	N/A
12/31/2015	0	-28	N/A	-24	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if ZSAN.Q's forecast earnings growth is above the savings rate (2%).

収益対市場: Insufficient data to determine if ZSAN.Q's earnings are forecast to grow faster than the US market

高成長収益: Insufficient data to determine if ZSAN.Q's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if ZSAN.Q's revenue is forecast to grow faster than the US market.

高い収益成長: Insufficient data to determine if ZSAN.Q's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if ZSAN.Q's Return on Equity is forecast to be high in 3 years time

This company is no longer active

Zosano Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus forecasts updated

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Consensus forecasts updated

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Consensus forecasts updated

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Consensus forecasts updated

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Zosano shares rise on migraine treatment NDA resubmission update

Consensus revenue estimates increase to US$5.17m

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Earnings miss expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: US$1.93

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

New 90-day high: US$0.81

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Zosano Pharma requests FDA meeting for its Qtrypta application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

Zosano Pharma EPS misses by $0.01

New 90-day low: US$0.36

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

Price target lowered to US$2.00

New 90-day low: US$0.64

New 90-day low: US$0.70

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - US$1.69

New 90-day high - US$1.22

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘